High-flow nasal oxygen vs. standard oxygen therapy in immunocompromised patients with acute respiratory failure: study protocol for a randomized controlled trial
Authors:
- Elie AzoulayEAElie Azoulay
- Virginie LemialeVLVirginie Lemiale
- Djamel MokartDMDjamel Mokart
- Saad NseirSNSaad Nseir
- Laurent ArgaudLALaurent Argaud
- Frédéric PèneFPFrédéric Pène
- Loay KontarLKLoay Kontar
- Fabrice BruneelFBFabrice Bruneel
- Kada KloucheKada Klouche
- François BarbierFBFrançois Barbier
- Jean ReignierJRJean Reignier
- Anabelle StoclinASAnabelle Stoclin
Open Access
- 5 March 2018
- journal article
- research article
- Published by Springer Nature in Trials
- Vol. 19 (1) , 1-11
Abstract
Acute respiratory failure (ARF) is the leading reason for intensive care unit (ICU) admission in immunocompromised patients. High-flow nasal oxygen (HFNO) therapy is an alternative to standard oxygen. By providing warmed and humidified gas, HFNO allows the delivery of higher flow rates via nasal cannula devices, with FiO2 values of nearly 100%. Benefits include alleviation of dyspnea and discomfort, decreased respiratory distress and decreased mortality in unselected patients with acute hypoxemic respiratory failure. However, in preliminary reports, HFNO benefits are controversial in immunocompromised patients in whom it has never been properly evaluated. This is a multicenter, open-label, randomized controlled superiority trial in 30 intensive care units, part of the Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique (GRRR-OH). Inclusion criteria will be: (1) adults, (2) known immunosuppression, (3) ARF, (4) oxygen therapy ≥ 6 L/min, (5) written informed consent from patient or proxy. Exclusion criteria will be: (1) imminent death (moribund patient), (2) no informed consent, (3) hypercapnia (PaCO2 ≥ 50 mmHg), (4) isolated cardiogenic pulmonary edema, (5) pregnancy or breastfeeding, (6) anatomical factors precluding insertion of a nasal cannula, (7) no coverage by the French statutory healthcare insurance system, and (8) post-surgical setting from day 1 to day 6 (patients with ARF occurring after day 6 of surgery can be included). The primary outcome measure is day-28 mortality. Secondary outcomes are intubation rate, comfort, dyspnea, respiratory rate, oxygenation, ICU length of stay, and ICU-acquired infections. Based on an expected 30% mortality rate in the standard oxygen group, and 20% in the HFNO group, error rate set at 5%, and a statistical power at 90%, 389 patients are required in each treatment group (778 patients overall). Recruitment period is estimated at 30 months, with 28 days of additional follow-up for the last included patient. The HIGH study will be the largest multicenter, randomized controlled trial seeking to demonstrate that survival benefits from HFNO reported in unselected patients also apply to a large immunocompromised population. ClinicalTrials.gov, ID: NCT02739451 . Registered on 15 April 2016.Keywords
Funding Information
- APHP (P150912)
This publication has 69 references indexed in Scilit:
- Managing critically Ill hematology patients: Time to think differentlyBlood Reviews, 2015
- Noninferiority TrialsJAMA, 2015
- Use of High-Flow Nasal Cannula Oxygen Therapy to Prevent Desaturation During Tracheal Intubation of Intensive Care Patients With Mild-to-Moderate Hypoxemia*Critical Care Medicine, 2015
- Rituximab versus Azathioprine for Maintenance in ANCA-Associated VasculitisNew England Journal of Medicine, 2014
- Intensive care in patients with lung cancer: a multinational studyAnnals of Oncology, 2014
- Humidification Performance of Two High-Flow Nasal Cannula Devices: A Bench StudyRespiratory Care, 2013
- Effect of High-Flow Nasal Cannula and Body Position on End-Expiratory Lung Volume: A Cohort Study Using Electrical Impedance TomographyRespiratory Care, 2013
- High-Flow Nasal Cannula Therapy in Do-Not-Intubate Patients With Hypoxemic Respiratory DistressRespiratory Care, 2013
- Delayed intensive care unit admission is associated with increased mortality in patients with cancer with acute respiratory failureLeukemia & Lymphoma, 2012
- Diagnostic Strategy for Hematology and Oncology Patients with Acute Respiratory Failure: Randomized Controlled TrialAmerican Journal of Respiratory and Critical Care Medicine, 2010